Concord Biotech (CONCORDBIO) Q4 24/25 earnings summary

Executive summary

• Achieved consolidated revenue of ₹1,200.1 Cr in FY25, up 18% year-over-year, with Q4FY25 revenue at ₹429.9 Cr, up 35% compared to Q4FY24.

• PAT increased 21% to ₹371.6 Cr for FY25, with Q4FY25 PAT up 48% year-over-year.

• Strategic investments made in Palvella Therapeutics (rare diseases) and CleanMax (renewable energy) to support growth and ESG goals.

• Commissioned a new injectable manufacturing facility, expanding into high-value segments and enhancing global regulatory compliance.

• Board recommended a final dividend of ₹10.70 per share for FY25, subject to shareholder approval.

Financial highlights

• FY25 revenue: ₹1,200.1 Cr (+18% YoY); Q4FY25 revenue: ₹429.9 Cr (+35% YoY).

• FY25 PAT: ₹371.6 Cr (+21% YoY); Q4FY25 PAT: ₹140.4 Cr (+48% YoY).

• FY25 EBITDA: ₹506.3 Cr (+17% YoY); Q4FY25 EBITDA: ₹190.4 Cr (+43% YoY).

• FY25 EBITDA margin: 42.2% (flat YoY); Q4FY25 EBITDA margin: 44.3% (+220 bps YoY).

• EPS for FY25 at ₹35.5, up from ₹29.4 in FY24.

Outlook and guidance

• Well positioned for accelerated growth, leveraging a broad API and formulation portfolio and new injectable capacity.

• No specific FY26 guidance; long-term CAGR target of 25% remains, with gradual progression from current 18%.

• Focus on scaling domestic and global presence, investing in R&D, and expanding product pipeline.

• Targeting growth in CDMO/CMO opportunities leveraging fermentation capabilities and available capacity.

• Injectable facility expected to contribute significantly over the next 3-4 years.